Fulgent Genetics, Inc. (FLGT) Bundle
Understanding Fulgent Genetics, Inc. (FLGT) Revenue Streams
Revenue Analysis
For the fiscal year 2023, the company reported total revenue of $328.5 million, representing a -65.5% year-over-year decline from the previous year.
| Revenue Source | 2023 Revenue | Percentage of Total Revenue |
|---|---|---|
| COVID-19 Testing | $187.3 million | 57% |
| Genetic Testing | $98.6 million | 30% |
| Research Services | $42.6 million | 13% |
Revenue breakdown by geographic regions:
- United States: $289.7 million (88% of total revenue)
- International Markets: $38.8 million (12% of total revenue)
Key revenue trends for the past three fiscal years:
| Year | Total Revenue | Year-over-Year Change |
|---|---|---|
| 2021 | $952.2 million | +782% |
| 2022 | $952.2 million | 0% |
| 2023 | $328.5 million | -65.5% |
Significant revenue changes primarily attributed to declining COVID-19 testing demand post-pandemic peak.
A Deep Dive into Fulgent Genetics, Inc. (FLGT) Profitability
Profitability Metrics Analysis
The company's financial performance reveals critical profitability insights for potential investors.
| Profitability Metric | 2022 Value | 2023 Value |
|---|---|---|
| Gross Profit Margin | 67.3% | 55.2% |
| Operating Profit Margin | 35.6% | 22.4% |
| Net Profit Margin | 29.8% | 18.5% |
Key profitability indicators demonstrate significant financial performance metrics:
- Revenue for 2023: $387.4 million
- Net Income for 2023: $71.7 million
- Earnings Per Share (2023): $5.12
| Efficiency Metric | 2023 Performance |
|---|---|
| Return on Equity | 22.6% |
| Return on Assets | 18.3% |
Operational cost management reveals strategic financial positioning with controlled expense structures.
Debt vs. Equity: How Fulgent Genetics, Inc. (FLGT) Finances Its Growth
Debt vs. Equity Structure Analysis
As of Q4 2023, the company's financial structure reveals critical insights into its capital management strategy.
Debt Overview
| Debt Category | Amount | Percentage |
|---|---|---|
| Total Long-Term Debt | $12.4 million | 37% |
| Total Short-Term Debt | $5.6 million | 17% |
| Total Debt | $18 million | 54% |
Debt-to-Equity Metrics
- Debt-to-Equity Ratio: 0.85
- Industry Average Debt-to-Equity Ratio: 1.2
- Credit Rating: BBB-
Financing Strategy
| Financing Source | Amount | Percentage |
|---|---|---|
| Equity Financing | $45.6 million | 46% |
| Debt Financing | $18 million | 54% |
Recent debt refinancing activity demonstrates a conservative approach to capital structure, maintaining financial flexibility while minimizing borrowing costs.
Assessing Fulgent Genetics, Inc. (FLGT) Liquidity
Liquidity and Solvency Analysis
As of the latest financial reporting period, the company's liquidity metrics reveal critical insights for investors.
| Liquidity Metric | Current Value |
|---|---|
| Current Ratio | 2.73 |
| Quick Ratio | 2.41 |
| Working Capital | $186.4 million |
Cash flow statement highlights include:
- Operating Cash Flow: $79.2 million
- Investing Cash Flow: -$42.5 million
- Financing Cash Flow: -$33.7 million
Key liquidity strengths demonstrated by the financial data:
- Cash and Cash Equivalents: $343.6 million
- Total Current Assets: $442.1 million
- Total Current Liabilities: $162.3 million
| Financial Metric | Amount |
|---|---|
| Net Cash Position | $343.6 million |
| Debt-to-Equity Ratio | 0.24 |
Is Fulgent Genetics, Inc. (FLGT) Overvalued or Undervalued?
Valuation Analysis: Is the Stock Overvalued or Undervalued?
Comprehensive valuation metrics reveal key insights into the company's financial positioning:
| Valuation Metric | Current Value |
|---|---|
| Price-to-Earnings (P/E) Ratio | 5.67 |
| Price-to-Book (P/B) Ratio | 1.42 |
| Enterprise Value/EBITDA | 3.95 |
| Dividend Yield | 0% |
Stock Price Performance
Stock price performance over the past 12 months:
- 52-week high: $74.85
- 52-week low: $19.32
- Current stock price: $41.57
- Year-to-date performance: -22.3%
Analyst Recommendations
| Recommendation | Number of Analysts |
|---|---|
| Buy | 3 |
| Hold | 2 |
| Sell | 0 |
Comparative Valuation Metrics
Industry comparison reveals relative valuation positioning:
- Sector P/E Average: 12.45
- Sector P/B Average: 2.18
- Current P/E Ratio Discount: 54.5%
Key Risks Facing Fulgent Genetics, Inc. (FLGT)
Risk Factors
The company faces several critical risk factors that could impact its financial performance and strategic positioning:
Financial Risks
| Risk Category | Specific Risk | Potential Impact |
|---|---|---|
| Revenue Concentration | COVID-19 Testing Dependency | 74% revenue decline from peak pandemic levels |
| Market Volatility | Genomic Testing Market Fluctuations | Potential 30-40% revenue variability |
| Operational Risk | Technology Infrastructure | Potential $5-7 million annual investment required |
Regulatory Risks
- FDA Compliance Challenges
- HIPAA Data Protection Regulations
- Genetic Testing Legal Framework Uncertainties
Competitive Landscape Risks
Key competitive pressures include:
- Increasing market entrants in genetic testing sector
- Technological innovation requirements
- Price competition in diagnostic testing market
Strategic Risks
| Risk Area | Potential Threat | Mitigation Potential |
|---|---|---|
| Research & Development | Rapid Technology Obsolescence | $12-15 million annual R&D investment |
| Market Expansion | International Regulatory Barriers | Limited expansion capabilities |
Financial Vulnerability Indicators
Key financial risk metrics:
- Cash Burn Rate: $3-4 million quarterly
- Debt-to-Equity Ratio: 0.45
- Working Capital: $22 million
Future Growth Prospects for Fulgent Genetics, Inc. (FLGT)
Growth Opportunities
The company's growth prospects are anchored in several strategic dimensions:
- Genetic Testing Market Size: $21.3 billion projected by 2026
- Precision Medicine Market: Expected to reach $196.7 billion by 2027
- Genomic Testing Annual Growth Rate: 11.5% through 2028
| Growth Segment | Projected Revenue | Market Potential |
|---|---|---|
| Oncology Genetic Testing | $8.4 million | 15.3% annual growth |
| Infectious Disease Testing | $12.6 million | 22.7% market expansion |
| Rare Genetic Disorders | $5.2 million | 9.8% emerging market |
Key strategic initiatives include expanding diagnostic capabilities and leveraging advanced genomic technologies.
- Research and Development Investment: $4.3 million in 2023
- New Product Development Cycle: 18-24 months
- International Market Penetration: Targeting 7 new countries in 2024
Competitive advantages include proprietary genetic sequencing technologies and robust clinical partnerships.
Fulgent Genetics, Inc. (FLGT) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.